Alonso Alconada, LorenaBarbazan, JorgeCandamio, SoniaFalco, Josep LluisAntón Rodríguez, CristinaMartín Saborido, CarlosFuster, GustavoSampedro, MabelGrande, CarlosLado, RubénSampietro Colom, LauraCrego, EladioFigueiras, SergioLeón Mateos, LuisLópez López, RafaelAbal, Miguel2017-11-172017-11-1720171699-3055http://hdl.handle.net/10641/1365Purpose: Management of metastatic disease in oncology includes monitoring of therapy response principally by imaging techniques like CT-Scan. In addition to some limitations, the irruption of liquid biopsy and its application in personalized medicine has encouraged the development of more efficient technologies for prognosis and follow-up of patients in advanced disease. Methods: PrediCTC constitutes a panel of genes for the assessment of Circulating Tumor Cells (CTC) in metastatic colorectal cancer patients, with demonstrated improved efficiency compared to CT-Scan for the evaluation of early therapy response in a multicenter prospective study. In this work, we designed and developed a technology transfer strategy to define the market opportunity for an eventual implementation of PrediCTC in the clinical practice. Results: This included the definition of the regulatory framework, the analysis of the regulatory roadmap needed for CE mark, a benchmarking study, the design of a product development strategy, a revision of intellectual property, a cost-effectiveness study and an expert panel consultation. Conclusion: The definition and analysis of an appropriate technology transfer strategy and the correct balance among regulatory, financial and technical determinants are critical for the transformation of a promising technology into a viable technology, and for the decision of implementing liquid biopsy in the monitoring of therapy response in advanced disease.engAtribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/Liquid biopsyMetastatic colorectal cancerRegulatory roadmapBenchmarkingProduct developmentIntellectual propertyCost-effectivenessExpert panelPrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.journal articleopen access